SAB Biotherapeutics (NASDAQ:SABS) Cut to “Strong Sell” at Zacks Research

Zacks Research cut shares of SAB Biotherapeutics (NASDAQ:SABS) from a hold rating to a strong sell rating in a research report report published on Thursday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on SABS. Guggenheim began coverage on shares of SAB Biotherapeutics in a research note on Friday, December 19th. They set a “buy” rating and a $15.00 target price on the stock. HC Wainwright decreased their price target on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th. UBS Group began coverage on shares of SAB Biotherapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $7.00 price target on the stock. Wall Street Zen cut shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of SAB Biotherapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, SAB Biotherapeutics has a consensus rating of “Moderate Buy” and an average price target of $10.00.

SAB Biotherapeutics Price Performance

NASDAQ:SABS opened at $4.15 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.50 and a current ratio of 9.46. The firm’s fifty day moving average is $4.02 and its two-hundred day moving average is $3.37. The firm has a market cap of $211.44 million, a price-to-earnings ratio of -1.79 and a beta of 0.59. SAB Biotherapeutics has a one year low of $1.00 and a one year high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.30). Research analysts expect that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $3,004,000. Millennium Management LLC purchased a new position in SAB Biotherapeutics during the fourth quarter worth about $1,212,000. Balyasny Asset Management L.P. purchased a new position in SAB Biotherapeutics during the fourth quarter worth about $1,778,000. ADAR1 Capital Management LLC boosted its holdings in SAB Biotherapeutics by 75.6% in the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock valued at $99,000 after purchasing an additional 11,344 shares during the last quarter. Finally, ExodusPoint Capital Management LP purchased a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at approximately $322,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.